Trial Profile
Study Evaluating the Safety and Efficacy of FOLFOX Plus Apatinib or FOLFIRI Plus Apatinib as Second-line Therapy in Metastatic Colorectal Cancer
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 05 Jan 2024
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary) ; Fluorouracil; Folinic acid; Irinotecan; Oxaliplatin
- Indications Adenocarcinoma; Carcinoma; Colorectal cancer
- Focus Therapeutic Use
- Acronyms XHZL
- 31 Dec 2023 Planned End Date changed from 1 Dec 2020 to 1 Dec 2024.
- 31 Dec 2023 Planned primary completion date changed from 1 Dec 2020 to 1 Dec 2022.
- 31 Dec 2023 Status changed from not yet recruiting to withdrawn prior to enrolment.